Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal.
Lehmann J, Buhl P, Giesinger JM, Wintner LM, Sztankay M, Neppl L, Willenbacher W, Weger R, Weyrer W, Rumpold G, Holzner B. Lehmann J, et al. Among authors: willenbacher w. J Med Internet Res. 2021 Jun 8;23(6):e26022. doi: 10.2196/26022. J Med Internet Res. 2021. PMID: 34100765 Free PMC article.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P. Ansell SM, et al. Among authors: willenbacher w. Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334. Blood Adv. 2023. PMID: 37530622 Free PMC article. Clinical Trial.
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.
Willenbacher W, Willenbacher E, Zelle-Rieser C, Biedermann R, Weger R, Jöhrer K, Brunner A. Willenbacher W, et al. Among authors: willenbacher e. Leuk Lymphoma. 2016;57(6):1478-81. doi: 10.3109/10428194.2015.1099646. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26413883 No abstract available.
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Willenbacher W, Thangavadivel S, Greil R, Willenbacher E, Weger R, Manzl C, Jöhrer K, Brunner A. Willenbacher W, et al. Among authors: willenbacher e. Leuk Lymphoma. 2016 Oct;57(10):2330-41. doi: 10.3109/10428194.2016.1144880. Epub 2016 Feb 16. Leuk Lymphoma. 2016. PMID: 26880040
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W; Austrian Myeloma Registry (AMR). Willenbacher E, et al. Among authors: willenbacher w. PLoS One. 2016 Mar 3;11(3):e0147381. doi: 10.1371/journal.pone.0147381. eCollection 2016. PLoS One. 2016. PMID: 26937956 Free PMC article.
Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.
Sztankay M, Neppl L, Wintner LM, Loth FL, Willenbacher W, Weger R, Weyrer W, Steurer M, Rumpold G, Holzner B. Sztankay M, et al. Among authors: willenbacher w. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13154. doi: 10.1111/ecc.13154. Epub 2019 Aug 29. Eur J Cancer Care (Engl). 2019. PMID: 31465136 Free PMC article.
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E, Willenbacher W, Weger R, Dominik W, Manzl C, Brunner A. Willenbacher E, et al. Among authors: willenbacher w. Ann Hematol. 2020 Sep;99(9):2125-2132. doi: 10.1007/s00277-020-04124-0. Epub 2020 Jul 1. Ann Hematol. 2020. PMID: 32613279 Free PMC article.
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, Wöll E, Verdorfer I, Gastl G, Willenbacher W, Weger R, Nachbaur D, Wolf D, Gunsilius E, Zschocke J, Steiner N. Locher M, et al. Among authors: willenbacher w. Am J Hematol. 2020 Dec;95(12):1562-1571. doi: 10.1002/ajh.25994. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32936982 Free PMC article. Clinical Trial.
The cancer patient's perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic.
Koinig KA, Arnold C, Lehmann J, Giesinger J, Köck S, Willenbacher W, Weger R, Holzner B, Ganswindt U, Wolf D, Stauder R. Koinig KA, et al. Among authors: willenbacher w. Cancer Med. 2021 Jun;10(12):3928-3937. doi: 10.1002/cam4.3950. Epub 2021 May 10. Cancer Med. 2021. PMID: 33973411 Free PMC article.
91 results